NCT04669600View on ClinicalTrials.gov

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

February 15, 2022

Study Completion Date

February 7, 2023

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

SAR445088 (BIVV020)

Pharmaceutical form:solution for injection

Trial Locations (9)

15006

Investigational Site Number :7240002, A Coruña

20007

Investigational Site Number :8400001, Washington D.C.

33321

Investigational Site Number :8400002, Tamarac

41013

Investigational Site Number :7240003, Seville

45147

Investigational Site Number :2760001, Essen

70852

Investigational Site Number :2030002, Ostrava - Poruba

2333 ZA

Investigational Site Number :5280001, Leiden

07120

Investigational Site Number :7240001, Palma de Mallorca

W12 0HS

Investigational Site Number :8260002, London

All Listed Sponsors
lead

Bioverativ, a Sanofi company

INDUSTRY

NCT04669600 - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter